Aldara (imiquimod) cream for early skin cancer and sun damage
Aldara (imiquimod) is a prescription immune-activating cream used to treat selected, thin skin cancers and sun-damage “precancer” (actinic keratoses). At The Skin Doctor, we use Aldara (imiquimod) mainly for:
Superficial basal cell carcinoma (sBCC) (1–3) — see (Superficial BCC)
Squamous cell carcinoma in situ (SCCis / Bowen’s disease) (4,5) — see (SCC in situ (Bowen’s))
Actinic keratosis (AK) in selected cases (6,7) — see (Actinic Keratosis) and (Actinic Keratosis Treatment)
If you’re deciding between topical treatments, also read:
(Laser-assisted photodynamic therapy (LA-PDT) for non-melanoma skin cancer)
Quick comparison
Comparison of Aldara to other field actinic keratosis treatments (Jump to table 1 below Field Treatment Comparison: Actinic Keratosis (AK))
Comparison of Aldara to other non melanoma skin cancer treatments (jump to table 2 below)
Book a 20 minute appointment with Dr Chris (Skin cancer treatment discussion)
When Aldara (imiquimod) is a good option
Aldara (imiquimod) can be a good choice when:
the lesion is confirmed (often by biopsy) to be suitable and thin/superficial (1,4)
you want to avoid (or delay) surgery where appropriate
the location or your scarring preference makes a non-surgical approach attractive
Aldara (imiquimod) is not suitable for every lesion. Depth, subtype, location, immune status, and diagnostic certainty matter.
If you have one to three spots you’re worried about, start with (Targeted Skin Spot Check (Up to 3 lesions)).
How Aldara (imiquimod) works
Aldara (imiquimod) activates immune signalling in the skin (including Toll-like receptor pathways), which helps your body recognise and destroy abnormal cells. (8,9)
A key concept: Aldara (imiquimod) works by creating an immune reaction. Some redness and inflammation is expected — and often correlates with response — but we still want the reaction to remain safe and controlled. (1–3)
How effective is Aldara (imiquimod)?
For properly selected superficial lesions, studies show clearance rates in the roughly 70–80% range depending on the protocol and how clearance is defined (clinical vs histological). (1–3)
For context, surgical removal of a suitable low-risk lesion usually has a higher cure rate, but involves a scar and surgical downsides. (10)
What patients often like about Aldara (imiquimod):
usually minimal scarring
no cutting, stitches, or surgical wound care
treatment is done at home (with structured follow-up)
Aldara (imiquimod) vs Efudix (5-fluorouracil): which is “easier”?
People often find Aldara (imiquimod) more tolerable than Efudix (5-fluorouracil), but reactions vary widely.
If you’re treating actinic keratoses (AK), we often prefer Efudix (5-fluorouracil) because the course can be more convenient and predictable — but Aldara (imiquimod) can still be appropriate in selected situations. (6,7)
Compare: (Efudix (5-fluorouracil))
How much Aldara (imiquimod) should I use?
More is not better.
A practical guide:
A thin film is the goal.
A pea-sized amount is usually enough for a small lesion area.
By about 10 minutes after applying Aldara (imiquimod), you generally shouldn’t see visible white cream sitting on the skin.
If you accidentally use too much, don’t panic — just use a little less next time.
How to use Aldara (imiquimod): step-by-step
Your exact plan should come from your doctor. A common regimen for selected superficial skin cancers is:
Apply Aldara (imiquimod) once daily, 5 days per week, for 6 weeks. (5–7)
1) Timing
Apply Aldara (imiquimod) 2–3 hours before bed so it can absorb and won’t rub off onto bedding. (6,7)
2) Clean the area
Wash with warm water
Avoid harsh cleansers or scrubs
Pat dry, then wait 10–15 minutes
3) Apply correctly
Use a glove (or wash hands thoroughly afterwards)
Apply Aldara (imiquimod) to the lesion plus the margin your doctor recommends (often around 5 mm, depending on the lesion and diagnosis)
Avoid eyes, nostrils, lips, and other mucous membranes (6,7)
4) Don’t occlude unless instructed
Do not cover the area with an airtight dressing unless your doctor tells you to. Occlusion can intensify the reaction and may increase side-effect risk. (6,7)
If you need cosmetic cover, a light, non-occlusive dressing may be reasonable — discuss this with your doctor first.
5) After applying
Wash hands well
After about 20 minutes you can usually apply moisturiser, sunscreen, and/or makeup as needed (as long as it doesn’t irritate the area)
6) Treatment area limits
Do not treat large areas unless specifically instructed. Product information limits treatment area and provides guidance on maximum surface area. (6,7)
7) Review after treatment
We normally review the area after the course is finished (often including dermoscopy) to check response and decide if further treatment or biopsy is needed.
What should I expect during treatment?
A typical timeline:
Week 1–2: mild redness/itching can start
Week 3–6: inflammation often ramps up (redness, crusting, soreness)
After finishing: the area gradually settles over weeks, and the final appearance continues to improve
Some areas (for example, the side of the nose) can swell and look dramatic. This can be normal — but if you’re worried, contact your treating doctor.
Side effects and risks of Aldara (imiquimod)
Aldara (imiquimod) is usually well tolerated when used correctly, but side effects can occur. (6,7)
Common local effects
redness, burning, itching
crusting / scabbing
swelling
weeping or mild erosions (6,7)
Pigment change (darkening or lightening)
Any significant inflammation can disrupt pigment cells and cause lighter or darker patches. Risk is higher if you get UV exposure during/after treatment.
Strict sun avoidance and sunscreen are important during treatment and for weeks afterwards.
If you’re prone to pigmentation (e.g., melasma), discuss this before starting:
(Melasma)
Scarring (uncommon, but possible)
Most people do not scar, but intense inflammation can scar in susceptible individuals. If scarring risk is a major concern, discuss alternatives such as:
Surgery (where appropriate)
Worsening facial redness / rosacea-type vessels (rare)
Inflammation can sometimes unmask or worsen facial redness and visible vessels. If you already have rosacea or you’re redness-prone, discuss options first:
Non-healing ulcer (higher risk on lower legs)
Lower legs have relatively reduced blood supply, and inflammation can occasionally lead to delayed healing. Lower-leg lesions should be managed cautiously and under close review.
Infection (uncommon)
Treated skin can look alarming without being infected. Seek review promptly if you have rapidly spreading redness, increasing pain/warmth, pus, or fevers/feeling unwell.
Who should not use Aldara (imiquimod)?
Aldara (imiquimod) generally should be avoided or used only under specialist guidance in situations such as:
pregnancy (6,7)
breastfeeding (product information advises caution due to limited data) (7)
immunosuppression (may be less effective; planning differs) (7)
Always tell your doctor if you are pregnant, trying to conceive, or breastfeeding, or if you take immunosuppressive medication.
When to contact your doctor urgently
Stop and seek medical advice if you develop:
severe pain, extensive ulceration, or rapidly worsening swelling
fever, rigors, or feeling systemically unwell
signs of spreading infection
eye involvement (especially eyelid swelling with visual symptoms)
Alternatives patients commonly consider
Depending on diagnosis and site, alternatives may include:
(Actinic Keratosis Treatment) (for precancer field treatment options)
surgery (often the highest-cure option when appropriate)
Book an appointment
If you’ve been prescribed Aldara (imiquimod), or you’re deciding between creams, LA-PDT, and surgery, we can help you choose the safest, most effective pathway for your lesion type and location.
Book a 20 minute appointment with Dr Chris (Skin cancer treatment discussion)
Or, for a few specific lesions: (Targeted Skin Spot Check (Up to 3 lesions))
Field Treatment Comparison: Actinic Keratosis (AK)
| Feature | LA-PDT (Laser-Assisted) | Efudix (5-fluorouracil) | Aldara (imiquimod) |
| Indicated For | Multiple/Field AKs | Multiple/Field AKs | Multiple/Field AKs |
| Effectiveness | ~90-95% clearance; highly effective for thick lesions. | ~75% full clearance of visible lesions. | ~70% – 85% clearance. |
| Delivery | In-clinic, doctor-led | At-home, self-applied | At-home, self-applied |
| Mechanism | Topical chemotherapy; blocks DNA synthesis. | Immune system stimulant; triggers local attack. | |
| Visible Reaction | Intense redness, crusting, and swelling (brief). | Significant redness, erosion, and “angry” scabbing. | Redness, weeping, and localized inflammation. |
| Systemic (Whole Body) Side Effects | None | 5–10% can develop flu-like illness, cramps, vomiting, or alopecia. Rare bone marrow suppression (life-threatening if DPD deficient). | 5–10% can develop flu-like illness, headaches, dizziness, or fatigue. |
| Discontinuation (Severe Side Effects) | None | ~5% stop early due to severe reactions or pain. | ~3% stop early due to systemic or local reactions. |
| Downtime | Short: 7–10 days for most healing. | Prolonged: 4–8 weeks (treatment + healing). | Prolonged: 4–8 weeks (treatment + healing). |
| Cosmetic Outcome | Excellent: Often improves overall skin texture. | Good: Slightly higher risk of pigment changes or scarring. Also worsens rosacea. | Good: Slightly higher risk of pigment changes or scarring. Also worsens rosacea. |
Table 1.
Treatment Comparison comparing Aldara to other options for non melanoma skin cancer (NMSC): At-a-Glance
| Feature | LA-PDT (Laser-Assisted) | Surgery | Efudix (5-fluorouracil) | Aldara (imiquimod) |
| Indicated For | sBCC, SCCis, nBCC* (10-15) | sBCC, SCCis, nBCC* | SCCis (3) | sBCC (2) |
| Effectiveness | ~94% – 100% ((10-14)) | ~97% | 70% (8) | ~80% (non-facial); 42–76% (facial) (9) |
| Delivery | In-clinic, doctor-led | In-clinic | At-home, self-applied (3) | At-home, self-applied (2) |
| Typical Course | 1–2 sessions | 1 session | Twice daily for 6 weeks | 5 days a week for 6 weeks |
| Mechanism | Laser ablation + light-activated cell death | Surgical excision | Topical chemotherapy (3) | Immune system stimulant (2) |
| Visible Reaction | Red, weeping area | Scarring | Red, weeping area | Red, weeping area |
| Systemic (whole body) side effects | None | None | 5-10% can develop flu like illness, abdominal cramps, persistent vomiting, bloody diarrhoea, alopecia, rare bone marrow suppression. Very rarely life threatening (18,19). | 5-10% can develop Flu like illness, headaches, dizziness, insomnia, diarrhoea(16,17,19). |
| Discontinuation before treatment complete due to severe side effects | None | None | 5% (19) | 3% (19) |
| Downtime | Short (days) | Weeks – 3 months (dependent on area and size) | Prolonged (weeks- two months) | Prolonged (weeks-two months |
| Cosmetic Outcome | Excellent (10-14) | Good (dependent on area and size) | Good (risk of pigment changes) | Good (risk of pigment changes) |
Table 2. *nBCC indication for LA-PDT may be considered off-label depending on clinical selection (36).
Frequently asked questions (FAQ)
How long does Aldara (imiquimod) take to work?
Most people notice increasing redness and irritation over the first 2–4 weeks, with the peak reaction often occurring during weeks 3–6 depending on the regimen. Healing and “settling” can continue for several weeks after you stop. (6,7)
Is a strong reaction a good sign?
A visible inflammatory response is common and often expected, because Aldara (imiquimod) works by activating local immune responses. But “stronger” isn’t always “better” — excessive ulceration or severe pain can increase complication risk and may need a pause or review. (6,7)
What if the area gets too painful or angry?
Contact your treating doctor. Common adjustments include short treatment breaks, changing frequency, and supporting the skin barrier with bland moisturisers. Do not “push through” severe pain, large ulcers, or rapidly worsening swelling without review. (6,7)
Can I put moisturiser on while using Aldara (imiquimod)?
Often yes, but timing matters. Many people apply moisturiser after the medication has been on the skin for a period (for example, after ~20 minutes) and choose bland, fragrance-free products. If moisturiser stings or worsens the reaction, stop and discuss alternatives with your doctor. (6,7)
Can I wear sunscreen or makeup?
Usually yes once the product has absorbed, but choose non-irritating products. If the skin is weeping or ulcerated, makeup can sting and may increase irritation. Sun protection is important during treatment and for weeks afterwards. (6,7)
Can I cover the area with a dressing?
Not usually. Occlusive (airtight) dressings can intensify the reaction and may increase side effects. If you need cover for cosmetic reasons, a light, non-occlusive dressing may be acceptable — discuss it with your doctor first. (6,7)
Can Aldara (imiquimod) be used near the eye, nose, or lips?
Extra caution is needed near mucous membranes. Accidental transfer to eyes or lips can cause significant irritation. If your lesion is close to these areas, you should only treat it under clear instructions (and sometimes we’ll recommend an in-clinic option instead). (6,7)
Will Aldara (imiquimod) leave a scar?
Most people do not scar, but scarring can happen — especially if inflammation is severe, prolonged, or the site heals poorly (such as lower legs). If scarring risk is a major concern, discuss alternatives like (Laser-assisted photodynamic therapy (LA-PDT) for non-melanoma skin cancer) or surgery where appropriate. (6,7)
Can Aldara (imiquimod) cause pigmentation changes?
Yes. Any significant inflammation can trigger temporary or permanent darkening (hyperpigmentation) or lightening (hypopigmentation), especially in pigment-prone skin types or with sun exposure. If pigmentation is a major concern, see (Post-Inflammatory Hyperpigmentation)and (Melasma). (6,7)
Is Aldara (imiquimod) safe in pregnancy or breastfeeding?
Aldara (imiquimod) is generally avoided in pregnancy, and product information advises caution in breastfeeding due to limited data. Always tell your doctor if you are pregnant, trying to conceive, or breastfeeding. (6,7)
What are alternatives if I don’t want Aldara (imiquimod)?
Depending on the diagnosis, alternatives may include (Efudix (5-fluorouracil)), (Laser-assisted photodynamic therapy (LA-PDT) for non-melanoma skin cancer), or surgery. For AK field treatment options, see (Actinic Keratosis Treatment). (6,7,10)
How do you confirm the cancer is gone after treatment?
We usually reassess clinically and with dermoscopy after the course. If there is any doubt, persistent change, or recurrence, a biopsy may be recommended to confirm clearance. (1–5)
References
Geisse J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology. 2004.
Shumack S, et al. Imiquimod 5% cream for the treatment of basal cell carcinoma (clearance and follow-up outcomes reported). Archives of Dermatology / JAMA Dermatology. 2002.
Bath-Hextall F, et al. Surgery versus imiquimod for basal cell carcinoma: comparative outcomes and recurrence data. Lancet Oncology. 2014.
Patel GK, et al. Topical imiquimod 5% cream for cutaneous squamous cell carcinoma in situ (Bowen’s disease): randomized controlled trial outcomes. Journal of the American Academy of Dermatology. 2006.
Peris K, et al. Imiquimod for Bowen’s disease: clinicopathologic regression in published series. Journal of the American Academy of Dermatology. 2006.
Aldara (imiquimod) Consumer Medicine Information (Australia).
Aldara (imiquimod) Australian Product Information.
Review evidence on imiquimod immune mechanism: innate immune activation via Toll-like receptor pathways.
Additional immunology reviews: local cytokine induction and antitumour immune effects of topical imiquimod.
Guideline-level evidence on relative cure rates for excision vs topical therapy in appropriately selected keratinocyte cancers.